New thrombolytic, anticoagulants, and platelet antagonists: The future of clinical practice

Journal of Thrombosis and Thrombolysis

Volumn 7, Issue 2, 1999, Pages 195-220

  Becker, Richard C ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARDEPARIN; BOXOL; CERTOPARIN; DALTEPARIN; DANAPAROID; DERMATAN SULFATE; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARINOID; LANOTEPLASE; LOW MOLECULAR WEIGHT HEPARIN; MINIPARIN; NADROPARIN; PARNAPARIN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; RETEPLASE; REVIPARIN; STAPHYLOKINASE; STREPTOKINASE; TINZAPARIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE;

ACUTE HEART INFARCTION; ARTERIAL CIRCULATION; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOT LYSIS; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MONITORING; FIBRINOLYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS; HEART INFARCTION; PRACTICE GUIDELINE; VEIN THROMBOSIS;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0032586318     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008845822884     Document Type: Review

References (129)

1. Burke AP, Farb A, Malcom GT, Liang Y-H, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary artery disease who die suddenly. N Eng J Med 1997;336:1276-1282.
2. Neuhaus KL, von Essen R, Vogt A, et al. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: Results of the German Recombinant Plasminogen Activator Study. J Am Coll Cardiol 1994;24:55-60.
3. Tebbe U, von Essen R, Smolarz A, et al. Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction. Am J Cardiol 1993;72:518-524.
4. Smalling RW, Bode C, Kalbfleisch J, et al. and the RAPID Investigators. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995;91:2725-2732.
5. Bode C, Smalling RW, Berg G, et al. and the RAPID Investigators. Randomized comparison of coronary thrombolysis achieved with double bolus reteplase (r-PA) and front-loaded "accelerated" alteplase (rt-PA) in patients with acute myocardial infarction. Circulation 1996;94:891-898.
6. INJECT Study Group. Randomized, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 1995;346:329-336.
7. The GUSTO III Investigators. A comparison of reteplase with a alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-1123.
8. Refino CJ, Paoni NF, Keyt BA, et al. A variant of tPA (T103N, KHRR-296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost 1993;70:313-319.
9. Cannon CP, McCabe CH, Gibson M, et al. and the TIMI 10A Investigators. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis Infarction (TIMI) 10A dose-ranging trial. Circulation 1997;95: 351-356.
10. Cannon CP, Gibson CM, McCabe CH, et al. for the TIMI 10b Investigators. TNK-tPA compared with front-loaded Alteplase in Acute Myocardial Infarction: Results of the TIMI 10B Trial. Circulation 1998;98:2805-2814.
11. ASSENT I
12. den Heijer P, Vermeer F, Ambrosioni E, et al. for the Im TIME investigators. Evaluation of a weight-adjusted single bolus plasminogen activator in patients with myocardial infarction. A Double-blind, randomized angiographic trial of Lanoteplase versus Alteplase. Circulation 1998;98: 2117-2125.
13. Lijnen HR, Stassen JM, Vanlinthout I, et al. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis. Thromb Haemost 1991;66:468-473.
14. Collen D, Bernaerts R, Declerck P, et al. Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization. Circulation 1996;94: 197-206.
15. Vanderschueren S, Barrios L, Kerdsinchai P, et al. for the STAR Trial Group. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995;92:2044-2049.
16. Pannekoek H, de Vries C, Van Zonnerveld A-J. Mutants of human tissue-plasminogen activator (tPA): Structural aspects and functional properties. Fibrinolysis 1988;2: 123-1332.
17. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989;86:2839-2843.
18. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am J Pathol 1989;134:1087-1097.
19. Teitel JM. Rosenberg RD. Protection of factor Xa from neutralization by heparin-antithrombin complex. J Clin Invest 1983;71:1383-1391.
20. Miletich JP, Jackson CM, Majerus PW. Properties of the factor Xa binding site on platelets. J Biol Chem 1978;253: 6908-6916.
21. Kakkar VV, Murray WJH. Efficacy and safety of low molecular weight heparin (CY216) in prevention postoperative venous thromboembolism: A co-operative study. Br J Surg 1985;72:786-791.
22. Koller M, Schoch U, Buchmann P, Largiader F, Von Felten A, Frick PG. Low molecular weight heparin (KABI-2165) as thromboprophylaxis in elective visceral surgery. A randomized double-blind study versus unfractionated heparin. Thromb Haemost 1986;56:243-246.
23. Schmidt-Huebner U, Bunte H, Freise G, et al. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Wochenschr 1984;62:349-353.
24. Cade JF, Wood M, Magnani HN, Westlake GW Early clinical experience of a new heparinoid, ORG 10172, in prevention of deep venous thrombosis. Thromb Res 1987;45:497-503.
25. Grunebaum L, Fricker JP, Wiesel ML, Vergnes Y, Cazenave JP, Barbier P, Kher A. Efficacy and safety of a low molecular weight heparin in prophylaxis of postoperative vein thrombosis after gynecologic surgery. Thromb Haemost 1987 (Suppl):420a.
26. Briel RC, Hermann P, Hermann C, Doller P. Low molecular weight heparin (fragmin) prophylaxis after gynecologic surgery. Thromb Haemost 1987;1(Suppl.):424A.
27. Le Gagneux F, Steg A, Le Guillov M. Subcutaneous enoxaparin versus placebo for preventing deep vein thrombosis after transurethral prostatectomy. Thromb Haemost 1987; 1(Suppl.) 413A.
28. ten Cate H, Henny CP, ten Cate JW, Buller HR, Dabhoiwala NF. Randomized double-blind, placebo controlled safety study of low molecular weight heparinoid in patients undergoing transurethral resection of the prostate. Thromb Haemost 1987;54:92-96.
29. Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E on behalf of the participants of the Groupe d'Etude de I'Enoxaparine (GENOX) multicentric trial. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 1988;75:128-131.
30. Turpie AGG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low molecular weight heparin (enoxaparine) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1987;315:929-929.
31. Le Balc'h, Landais A, Butel, Weill D, Pascariello JC, Planes A. Enoxaparin (Lovenox®), versus standard heparin in prophylaxis of deep vein thrombosis after total hip replacement. Thromb Haemost 1987;1(Suppl.):892A.
32. Potron G, Barre J, Droulle C, Baudyillard JC, Barbier P, Kher A. Thrombosis prophylaxis with low molecular weight heparin (KABI 2165) and calcium heparin in patients with total hip replacement. Thromb Haemost 1987;1(Suppl.): 421A.
33. Planes A, V Vochelle, C Mansat. Prevention of deep vein thrombosis after total hip replacement by enoxaparine: One daily injection of 40 mg versus two daily injections of 20 mg. Thromb Haemost 1987;1(Suppl.)415A.
34. Breyer HG, Rahmarzdet R, Bacher P, Werner B. LMW-heparin versus heparin-DHE in orthopedic surgery. Thromb Haemost 1987;1(Suppl.):890A.
35. Barsotti J, Dabo B, Andrew J, Alison D, Leroy J, Delahousse B. Prevention of deep vein thrombosis by enoxaparine after surgery for fracture of femoral neck. Once daily injection of 40 mg versus two daily injection of 20 mg. Thromb Haemost 1987;1(Suppl.):891A.
36. Planes A, Vochelle N, Ferru J, Przyrowski D, Clerc J, Fagola M, Planes M. Enoxaparine low molecular weight heparin: Its use in the prevention of deep venous thrombosis following total hip replacement. Haemostasis 1986;16:152-158.
37. Dahan R, Houlbert D, Caulin C, et al. Prevention of deep thrombosis in elderly medical inpatients by a low molecular heparin: A randomized double-blind trial. Haemostasis 1986;16:159-164.
38. Aquino JP, Gambier A, Durcross JJ. Prevention of thromboembolic accidents in elderly subjects with Fraxiparine®. In: Bounameaux H, Samama M, ten Cate JW, eds. Fraxiparin Second International Symposium Recent Pharmacological and Clinical Data. Stuttgart: Schattauer, 1990:51-54.
39. Turpie AGG, Hirsh J, Jay RM, et al. Double-blind randomized trial of ORG 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987;11:523-526.
40. Green D, Lee MY, Lim AC, et al. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. Ann Intern Med 1990;113:571-574.
41. Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind and randomized placebo controlled trial of low molecular weight heparin once daily to prevent deep vein thrombosis in acute ischemic stroke. Semin Thromb Hemost 1990;16(Suppl.):25-33.
42. Yelnik A, Dizien O, Bussel B, Schouman-Claeys E, Frija G, Pannier S, Held JP. Systematic lower limb phlebography in acute spinal cord injury in 147 patients, Paraplegia 1991;29: 253-260.
43. Turpie AGG, Gent M, Côte R, et al. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study. Ann Intern Med 1992;117:353-357.
44. Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kübler W, Heene DL. Randomized controlled study of heparin in low molecular Weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 1990;59:639-650.
45. Scala P-J, Thiollet M, Midavaine M, et al. Deep venous thrombosis and left ventricular thrombosis prophylaxis by low molecular weight heparin in acute myocardial infarction. Haemostasis 199?;20:368-369.
46. Nesvold A, Kontny F, Abildgaard U, Dale J. Safety of high doses of low molecular weight heparin (Fragmin) in acute myocardial infarction. A dose-finding study. Thromb Res 1991;64:579-587.
47. Bratt G. Törnebohm E, Granquist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985;54:813-817.
48. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;236:975-982.
49. Vogel G, Machulik M. Efficacy and safety of a low molecular weight heparin (LMW-heparin Sandoz) in patients with deep vein thrombosis. Thromb Haemost 1987;59:120.
50. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of venous thromboembolism with low molecular weight heparin (Fragmin). Circulation 1989;80:935-940.
51. Bratt G, Aberg W, Johannsson M, Törnebohm E, Granquist S, Lockner D. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1991;64:506-510.
52. Harenberg J, Huck K, Bratsch H, et al. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemostasis 1990;20:205-219.
53. Duroux P. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study. Thromb Haemost 1991;65:251-256.
54. Prandoni P, Lensing AWA, B Büller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancelet 1992;339:441-445.
55. Holm HA, Ly B, Handeland GF, et al. Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated with low molecular weight heparin. Haemostasis 1986;16:30-37.
56. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial. Thromb Haemost 1992;68:14-18.
57. Holmström M, Berglund M-C, Granquist S, Bratt G, Torneböhm E, Lockner D. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. Thromb Res 1992;67:49-55.
58. Théry C, Simonneau G, Meyer G, et al. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparin) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation 1992;85:1380-1389.
59. Lockner D, Johansson M, Aberg W, Bratt G, Granquist S. Fragmin (Kabi) subcutaneously once or twice daily in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1989;62:526.
60. A Collaborative European Multicentre Study. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991; 65:251-256.
61. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153: 1541-1546.
62. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch Intern Med 1995;155:601-607.
63. Dieval J, Moriniére P, Roussel B, Bayrou B, Fournier A, Delobel J. Anticoagulation in hemodialysis sessions with a low molecular weight heparin (CY 222). J Mal Vasc 1987; 12:114-118.
64. Massonnet-Castel S, Pelissier E, Bara L, et al. Partial reversal of low molecular weight heparin (PK 10169) and anti-Xa activity by protamine sulfate. Haemostasis 1986;16:139-146.
65. Bendetowicz AV, Kai H, Knebel R, Caplain H, Hemker HC, Lindhout T, Béguin S. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma - A study in human volunteers. Thromb Haemost 1994;72:705-712.
66. Melandri G, Semprini F, Cervi V, Candiotti N, Branzi A, Palazzini E, Magnani B. Comparison of the efficacy of low molecular weight heparin (parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects. Am J Cardiol 1993;72:450-454.
67. Dehmer GJ, Fisher M, Tate DA, Teo S, Bonnem EM. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. Circulation 1995;91:2188-2194.
68. Landolfi R, de Candia E, Rocca B, Ciabattoni G, Antinori A, Masetti R, Patrono C. Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis "in vivo". Thromb Haemost 1994;72:942-946.
69. Young E, Walls P, Holloway S, Weitz J, Ex vivo and in vitro evidence that low molecular weight heparin exhibits less binding to plasma proteins that unfractionated heparin. Thromb Haemost 1994;71:300-304.
70. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-318.
71. The FRISC Study Group. Low molecular weight heparin during unstability in coronary artery disease. Lancet 1996 ;347:561-568.
72. Klein W, Buchwald A, Hilli SE, et al. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997;96:61-68.
73. Cohen M, Demers C, Gurfinkel EP for the ESSENCE Investigators. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
74. Fernandez-Aviles F, Alonso J, Duran JM, et al. Absence of bleeding and subacute occlusion after Palmaz-Schatz coronary stenting using a new antithrombotic regimen. J Am Coll Cardiol 1995;1(Suppl. A):196A.
75. Morice M-C, Bourdonnec C, Lefevre T, et al. Coronary stenting without coumadin phase. Circulation 1994;90:2-25.
76. Zidar JP, Kruse KR, Berkowitz SD, et al. Low molecular weight heparin and elective stenting: The ENTICES Trial. Presented at the American Heart Association Meetings, Orlando, FL, November 9-13, 1997.
77. Glick A, Laniado S, Keren G. Low molecular weight heparin after acute MI can prevent recurrence of acute cardiac events after thrombolytic treatment. Presented at the American Heart Association Meetings, Orlando, FL, November 9-13, 1997.
78. Wilson C, Baird S, Trouton T. Enoxaparin versus unfractionated heparin after thrombolysis for acute myocardial infarction. Presented at the American Heart Association Meetings, Orlando, FL, November 9-13, 1997.
79. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, et al. Adjusted versus fixed doses of the low molecular weight heparin fragmin in the treatment of deep venous thrombosis. Thromb Haemost 1994;71:698-702.
80. Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985;39:631-636.
81. Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990;39:107-112.
82. Bratt G, Tornebohm E, Grnaqvist S, Aberq W, Lockner D. A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1989;59:813-817.
83. Palm M, Mattsson C, Magnus Svahn C, Weber M. Bleeding times in rats treated with heparin, heparin fragments of high and low anticoagulant activity and chemically modified heparin fragments of low anticoagulant activity. Thromb Haemost 1990; 64:127-132.
84. Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982;59:1239-1245.
85. Peyrou V, Lormeau JC, Caranobe C, et al. Pharmacological properties of CY 216 and of its ACLM and BCLM components in the rabbit. Thromb Haemost 1994;72:268-274.
86. Koller M, Schoch U, Buchmann P, Largiader F, Fon Felten A, Frieck PG. Low molecular weight heparin (Kabi 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin. Thromb Haemost 1986;56:243-246.
87. Bergqvist D, Burmark US, Frisell J, Lindblad B, Risberg B, Torngren S, Walling G. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. Aprospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986;73:204-208.
88. Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of post operative thrombosis. Br J Surg 1988;75:128-131.
89. Nieuwenhauis K, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991;78:2337-2343.
90. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard multicenter trial on prevention of postoperative thrombosis. Br J Surg 1986;73:204-208.
91. Hemker H, Béguin S, Bendetowicz A, Wielders S. The determination of the levels of unfractionated heparin and low molecular weight heparins in plasma: Their effect on thrombin mediated feedback reactions in vivo. Preliminary results after subcutaneous injection. Haemostasis 1991;21:258-272.
92. De Swart CAM, Nijmeyer B, Roelofs JMM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood 1982;60:1251-1258.
93. The TIMI 11A Investigators. Dose ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-1482.
94. Shaughnessy SG, Young E, Deschamps P, Hirsh J. The effects of low molecular weight heparin and standard heparin on calcium loss from fetal rat calvaria. Blood 1995;86: 1368-1373.
95. Hoppenstead D, Racanelli A, Walenga JM, Fareed J. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin. Sem Thromb Hemost 1989;15:378-385.
96. Gent M, Hirsh J, Ginsberg JS, et al. Low-molecular-weight heparinoid Orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation 1996;93:80-84.
97. de Valk HW, Banga JD, Wester JWJ, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med 1995;123:1-9.
98. Magnani HN. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993;70:554-561.
99. Hynes Ro. Integrins: A family of cell surface receptors. Cell 1987;48:549-54.
100. Plow EF, Ginsberg MH. Cellular adhesion:GPIIb/IIIa as a prototypic adhesion receptor. Prog Hemostas Thromb 1989; 9:117-56.
101. Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
102. Albeda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J 1990;4:2868-2880.
103. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330: 956-61.
104. Topol EJ, Califf RM, Weisman HF, et al. on behalf of the EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994;343:881-886.
105. 3 blockade with percutaneous coronary intervention. JAMA 1997;278:479-484.
106. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336: 1689-1696.
107. Simoons ML, Jan de Boer M, van den Brand JBM, et al. and the European Cooperative Study Group. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596-603.
108. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention, in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435.
109. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (Abciximab) therapy. Circulation 1997;95:809-813.
110. Théroux P, Kouz S, Roy L, et al. on behalf of the investigators. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 1996;94:899-905.
111. PARADIGM Investigators. Combined thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor Lamifiban: Results of the platelet aggregation receptor antagonist dose investigation receptor antagonist dose investigations and reperfusion gain in myocardial infarction (PARADIGM) Trial. J Am Coll Cardiol 1998:32:2003-2010.
112. PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIa inhibitor), heparin, or both in unstable angina. Circulation 1998;97:2386-2395).
113. Müller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J. Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation 1997;96:1130-1138.
114. Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536-542.
115. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-1453.
116. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM Plus) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIc receptor with tirofiban in unstable angina and non-Q wave MI. N Eng J Med 1998;338:1488-1497.
117. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Eng J Med 1998;338:1498-1505.
118. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80(4A):11B-20B.
119. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-1227.
120. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 1996;94:2083-2089.
121. The IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349:1422-1428.
122. Ohman EM, Kleiman NS, Gacioch G, et al. for the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997;95:846-854.
123. Harrington RA. Design and methodology of the PURSUIT trial. Evaluating eptifibatide for acute ischemic coronary syndromes. Am J Cardiol 1997;80:34B-38B.
124. Szalony JA, Haas NF, Salyers AK, Taite BB, Nicholson NS, Mehrota DV, Feigen LP. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. Circulation 1995;91:411-416.
125. Kereiakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral Xemilofiban in 170 patients after coronary stent deployment. Circulation 1997;96:1117-1121.
126. Kereiakes DJ, Runyon JP, Kleiman NS, et al. Differential dose-response to oral Xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. Circulation 1996;94:906-910.
127. Kereiakes DJ, Kleiman NS, Ferguson JJ for the ORBIT Investigators. Pharmacodynamic efficacy, clinical safety, and outcomes following prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral X Xemilofiban: Results of a multicenter placebo-controlled randomized trial. Circulation 1998, in press.
128. Cannon CP, McCabe CH, Borzak S for the TIMI 12 Investigators. A randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients post an acute coronary syndrome: Results of the TIMI 12 trial. Circulation 1998;97:340-349.
129. 2T purinoceptor antagonists: Definition of the role ADP in arterial thrombosis. Trends Pharm Scie 1995;16:179-181.